ATE243319T1 - Bor-neutronen-einfangtherapie unter verwendung von pre-targeting-methoden - Google Patents

Bor-neutronen-einfangtherapie unter verwendung von pre-targeting-methoden

Info

Publication number
ATE243319T1
ATE243319T1 AT97934209T AT97934209T ATE243319T1 AT E243319 T1 ATE243319 T1 AT E243319T1 AT 97934209 T AT97934209 T AT 97934209T AT 97934209 T AT97934209 T AT 97934209T AT E243319 T1 ATE243319 T1 AT E243319T1
Authority
AT
Austria
Prior art keywords
tumor cells
conjugate
boron
administering
allowing
Prior art date
Application number
AT97934209T
Other languages
English (en)
Inventor
Gary L Griffiths
Serengulam V Govindan
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of ATE243319T1 publication Critical patent/ATE243319T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1078—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an immunoglobulin, i.e. being an (anti)-anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97934209T 1996-07-26 1997-07-23 Bor-neutronen-einfangtherapie unter verwendung von pre-targeting-methoden ATE243319T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/687,626 US5846741A (en) 1992-08-21 1996-07-26 Boron neutron capture therapy using pre-targeting methods
PCT/US1997/012558 WO1998004917A1 (en) 1996-07-26 1997-07-23 Boron neutron capture therapy using pre-targeting methods

Publications (1)

Publication Number Publication Date
ATE243319T1 true ATE243319T1 (de) 2003-07-15

Family

ID=24761159

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97934209T ATE243319T1 (de) 1996-07-26 1997-07-23 Bor-neutronen-einfangtherapie unter verwendung von pre-targeting-methoden

Country Status (11)

Country Link
US (1) US5846741A (de)
EP (1) EP0920623B1 (de)
JP (1) JP2000516217A (de)
AT (1) ATE243319T1 (de)
AU (1) AU732510B2 (de)
CA (1) CA2261791A1 (de)
DE (1) DE69722937T2 (de)
DK (1) DK0920623T3 (de)
ES (1) ES2201309T3 (de)
PT (1) PT920623E (de)
WO (1) WO1998004917A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228362B1 (en) * 1992-08-21 2001-05-08 Immunomedics, Inc. Boron neutron capture therapy using pre-targeting methods
US7011812B1 (en) * 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
WO1997041898A1 (en) * 1996-05-03 1997-11-13 Immunomedics, Inc. Targeted combination immunotherapy of cancer
US6359111B1 (en) 1998-05-28 2002-03-19 Neorx Corporation Opioid receptor targeting
US7833528B2 (en) * 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
DE19909373A1 (de) * 1999-03-03 2000-10-05 Ugichem Neue PNA-Monomere, daraus resultierende PNA-Oligomere und deren Verwendung
US6525224B1 (en) 1999-06-08 2003-02-25 Northern Illinois University Fused polyhedron borane dianion
US7122172B1 (en) 2000-03-08 2006-10-17 Gerhart Graupner Methods and compositions for targeted drug delivery
US7906103B2 (en) * 2000-03-08 2011-03-15 Gerhard Graupner Methods and compositions for targeted drug delivery
WO2001097855A2 (en) * 2000-06-20 2001-12-27 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
US7195923B2 (en) * 2001-01-31 2007-03-27 Scripps Laboratories, Inc. Ratiometric determination of glycated protein
GB0112844D0 (en) * 2001-05-25 2001-07-18 Psimei Pharmaceuticals Plc Neutron capture therapy
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
MXPA05008222A (es) 2003-01-31 2005-10-05 Immunomedics Inc Metodos y composiciones para administrar agentes terapeuticos y de diagnostico.
WO2008144908A1 (en) * 2007-05-29 2008-12-04 Christopher Mott Methods and systems for circadian physiology predictions
EP2319850B1 (de) * 2008-07-24 2017-03-29 Stella Pharma Corporation MIT BSH VERSETZTE OPTISCH AKTIVE alpha-AMINOSÄURE UND SYNTHESEVERFAHREN DAFÜR
WO2012040514A2 (en) * 2010-09-23 2012-03-29 Biocept, Inc. Methods and reagents for signal amplification
US9234048B2 (en) 2012-01-18 2016-01-12 Wisconsin Alumni Research Foundation Boronate-mediated delivery of molecules into cells
US9732101B2 (en) 2012-01-18 2017-08-15 Wisconsin Alumni Research Foundation Bioreversible boronates for delivery of molecules into cells
JP5924795B2 (ja) 2014-06-13 2016-05-25 テンボロン オイ 複合体
CN110279858B (zh) * 2019-07-26 2021-02-19 浙江大学 一种具备细胞核靶向性的含硼制剂及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5443813A (en) * 1991-06-06 1995-08-22 Associated Universities, Inc. Loading and conjugating cavity biostructures
US5405598A (en) * 1992-02-24 1995-04-11 Schinazi; Raymond F. Sensitizing agents for use in boron neutron capture therapy
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
US5455022A (en) * 1993-09-09 1995-10-03 Associated Universities, Inc. Halogenated sulfidohydroboranes for nuclear medicine and boron neutron capture therapy
US5599796A (en) * 1993-12-02 1997-02-04 Emory University Treatment of urogenital cancer with boron neutron capture therapy
DE69638134D1 (de) * 1995-06-07 2010-04-08 Immunomedics Inc Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort
WO1997029114A1 (en) * 1996-02-08 1997-08-14 Board Of Regents Of The University Of Washington Biotin-containing compounds, biotinylation reagents and methods
WO1997041898A1 (en) * 1996-05-03 1997-11-13 Immunomedics, Inc. Targeted combination immunotherapy of cancer

Also Published As

Publication number Publication date
WO1998004917A1 (en) 1998-02-05
US5846741A (en) 1998-12-08
AU732510B2 (en) 2001-04-26
AU3732397A (en) 1998-02-20
DE69722937T2 (de) 2004-05-19
ES2201309T3 (es) 2004-03-16
DE69722937D1 (de) 2003-07-24
EP0920623B1 (de) 2003-06-18
PT920623E (pt) 2003-10-31
DK0920623T3 (da) 2003-10-06
EP0920623A1 (de) 1999-06-09
JP2000516217A (ja) 2000-12-05
EP0920623A4 (de) 2000-03-29
CA2261791A1 (en) 1998-02-05

Similar Documents

Publication Publication Date Title
ATE243319T1 (de) Bor-neutronen-einfangtherapie unter verwendung von pre-targeting-methoden
BR0012196A (pt) Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado
AU2640795A (en) Boron-containing hormone analogs and methods of their use in imaging or killing cells having hormone receptors
HUT66103A (en) Method for producing humanized chimeric anti-icam-1 antibodies
BR0315161A (pt) Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição
EP1092772A4 (de) Antikörper gegen eine lar-phosphatase untereinheit
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
de Noronha et al. Prevention of oncornavirus-induced sarcomas in cats by treatment with antiviral antibodies
EP0679093A1 (de) Methode zum überbringen von agenzien an zielzellen.
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
DK121683D0 (da) Fremgangsmade til fremstilling af immunoenzymatiske konjugater
MX9709324A (es) Compuestos terapeuticos que comprenden anticuerpos anti receptores fc.
PT1162997E (pt) Antigenio de staphylococcus e a respectiva vacina
AU1213588A (en) Macromolecular platinum antitumor compounds
WO2003089593A3 (en) Adjuvant enhanced immunotherapy
DE69731836D1 (de) Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann
ATE359821T1 (de) Bor-neutronenfangtherapie unter verwendung von pre-targeting-methoden
NO965395D0 (no) Humane, monoklonale antistoffer som er spesifikke mot cellecyklus-uavhengig gliom-overflateantigen
DK0529175T3 (da) Konjugater chelaret med paramagnetiske metaller til målsøgning
AU3991899A (en) Verotoxin b subunit for immunization
PT828848E (pt) Preparacao de compostos hidroxi por bioconversao com dioxigenase

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0920623

Country of ref document: EP

REN Ceased due to non-payment of the annual fee